Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes
Absolute contraindications to GLP-1 receptor agonists include: Personal history of medullary thyroid carcinoma Family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy (for weight management indications) Severe gastrointestinal disease, including gastroparesis Patients should be specifically questioned about these conditions during pre-treatment evaluation
The injection is typically self-administered by the patient at home after an initial in-clinic training session
Projections show continued explosive growth: From 2025 to 2030, Ozempic, Rybelsus, Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are forecasted to generate $400 billion in additional U.S
Unsurprisingly, not every new AOM asset delivered on those expectations in subsequent phase 2 or phase 3 trials, let alone setting ever more spectacular benchmarks for weight loss, while investors increasingly recognised the importance of a clean tolerability profile alongside compelling efficacy [1]
